By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting out of Washington, District of Columbia, by NewsRx editors, research stated, "Clinical trials demonstrated that metformin increases the efficiency of systemic therapy in cancer patients. We examined whether the efficacy of conventional treatment of differentiated thyroid cancer (DTC) is affected by therapy with metformin in diabetic patients."
Our news journalists obtained a quote from the research from Washington Hospital Center, "We compared the rate of complete response (CR) between diabetics who were treated with metformin (group MF+; n = 34) or not treated (group MF-; n = 21) and control nondiabetic patients (group C; n = 185). We also examined the effects of metformin on DTC cells in vitro. The groups were comparable in terms of age, sex, body mass index, diabetes management, frequencies of multifocal tumor growth, extrathyroidal extension, and locoregional and distant metastases. Tumor size was significantly smaller in the MF+ group compared with the MF- and C groups (1.37 +/- 0.97 vs 2.44 +/- 1.49 vs 2.39 +/- 1.73 cm, respectively; P = .026). A multivariate model revealed that extrathyroidal extension (P = .018), distant metastases (P = .0001), and lack of treatment with metformin of diabetics (P = .0001) decreased the likelihood of CR. A Cox hazards model revealed that age (P = .025), locoregional metastases (P = .022), distant metastases (P = .003), and lack of treatment with metformin of patients with diabetes (P = .014) are associated with increased risk for shortened progression-free survival. In vitro data revealed that metformin inhibited cancer cell growth, activated cAMP-inducible protein kinase (5'-AMP-activated protein kinase [AMPK]), and down-regulated p70S6K/pS6. Metformin potentiated H2O2-inducible activation of AMPK but attenuated pERK and p70S6K. Tumors from MF+ patients demonstrated a lower level of phospho-p70S6K compared with the MF- group. Tumor size is smaller in patients treated with metformin, suggesting inhibition of tumor growth by the drug. Among diabetics, the absence of metformin therapy is an independent factor for decreased likelihood of CR and increased risk of shorter progression-free survival."
According to the news editors, the research concluded: "In vitro data suggest that p70S6K/pS6 is likely a molecular target of metformin in DTC cells."
For more information on this research see: Treatment With Metformin Is Associated With Higher Remission Rate in Diabetic Patients With Thyroid Cancer. Journal of Clinical Endocrinology & Metabolism, 2013;98(8):3269-3279. Journal of Clinical Endocrinology & Metabolism can be contacted at: Endocrine Soc, 8401 Connecticut Ave, Suite 900, Chevy Chase, MD 20815-5817, USA. (The Endocrine Society - www.endo-society.org/; Journal of Clinical Endocrinology & Metabolism - jcem.endojournals.org/)
Our news journalists report that additional information may be obtained by contacting J. Klubo-Gwiezdzinska, Washington Hosp Center, Dept. of Med, Div Endocrinol, Washington, DC 20010, United States. Additional authors for this research include J. Costello, A. Patel, A. Bauer, K. Jensen, M. Mete, K.D. Burman, L. Wartofsky and V. Vasko (see also technology.html">Biotechnology).
Keywords for this news article include: Antidiabetic Agents, Biotechnology, Drugs, Diabetes, Oncology, Metformin, Treatment, Washington, Biguanides, United States, Endocrinology, Thyroid Cancer, Non-Sulfonylureas, Thyroid Neoplasms, Cancer Gene Therapy, Hypoglycemic Agents, District of Columbia, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC